Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Özet

Here, we present a detailed protocol for proteomic analysis of the whole kidney, isolated cortical tubule, and medullary proteomes. The study also compares regional proteomes in a diabetic mouse model and non-diabetic mice.

Özet

Defining the sequence of events in renal disease is the cornerstone of clinical practice in the nephrologist toolkit. Tissue proteomic analyses are a significant approach to understanding the fundamental physiological and molecular processes of renal pathophysiology. The methods and protocols we present here will allow for the molecular dissection of the kidney in each specific region of interest related to disease sequelae. To determine the effects of disease on specific kidney regions and structures with unique functions, the goals of this protocol are to demonstrate simplified mouse kidney compartmentalization and renal cortical tubule isolation techniques in tandem with streamlined label-free quantitative proteomic workflows. Combining these methods will assist in the identification of perturbed molecular patterns in the whole kidney, medullary compartments, and cortical tubule structures of kidneys, with the ultimate and eventual goal of single-cell proteomics in pathological contexts. Applying these methods in virtually any disease model will be helpful in delineating mechanisms of pathology related to kidney dysfunction.

Giriş

Chronic kidney disease (CKD) is a major concern in modern medicine, amounting to over $86 billion in healthcare expenditures in the United States alone¹. Worldwide, the incidence of CKD is increasing with the prevalence of diabetes and associated renal comorbidities. Close to 14 % of the US population has CKD (USRDS 2024 annual report). Furthermore, diabetic nephropathy is a form of CKD and the leading cause of end-stage renal disease (ESRD), and 60% of ESRD patients have diabetes^1,2,3. Diabetes affects all kidney structures and cell types of nephrons, the functional unit of kidneys. As shown in Figure 1, different portions of nephrons are contained in the kidney cortex and medulla regions. The majority of the kidney is composed of tubules. Renal tubule dysfunction and structural lesions significantly contribute to the development of diabetic nephropathy (DN), and these changes correlate well with the rate of renal function decline^4,5,6,7,8. Early in diabetes, in response to increased glucose and associated sodium uptake and membrane transport protein demands in all tubule segments, tubules undergo hypertrophy. With increased microvascular injury later in diabetes, tubules exhibit atrophy and dilation, while there is fibrosis and expansion of the interstitium⁹. Previous studies from our lab have found altered proteomes and an abundance of stress response proteins in cortical tubules of diabetic mice^10,11. The medulla is important for regulating urine concentration, and dysfunction during kidney disease is associated with oxidative stress, with diabetes leading to decreased oxygen tension in this region of the kidney due to increased oxygen consumption from metabolic activities, increased activity of membrane transport proteins, and microvascular injury^12,13,14.

Understanding the detailed mechanisms of development and progression of DN is an ongoing effort that will require novel and integrated approaches invoking modeling of disease and molecular profiling of signaling processes, adaptive changes in cellular protein dynamics, and precise definition of renal cell and tissue components affected by injury in chronic conditions. Proteomics, metabolomics, and transcriptomics offer the possibility to analytically probe the molecular mechanisms of kidney diseases. Omics is a relatively new field that utilizes systems biology approaches to gain a more global understanding of biological systems. Proteomics has been a powerful Omics tool in nephrology in recent decades. Biomarker research has expanded within the past 20 years, as indicated in the growth in publications, though extensive work is necessary to fully implement these findings into the clinic¹⁵. With the widely different tubule cell populations and respective functional roles within the renal cortex and medulla, proteomic analysis of whole kidneys can mask unique changes associated with specific structures within these different regions. Therefore, the goals of this study are to demonstrate the separation of the renal cortex and medulla, as well as the separation of cortical tubules from glomeruli, followed by detailed protocols for the preparation of protein extracts from isolated structures for state-of-the-art mass spectrometry and bioinformatics analyses. Mouse models of diabetic nephropathy are instrumental in defining mechanisms of disease progression. For this study, we used the OVE26 transgenic mouse, which develops early-onset type I diabetes and shows features of early and late-stage DN in humans, including 1) an early rise and later decline in glomerular filtration rate, 2) renal hypertrophy, 3) glomerular basement membrane thickening and mesangial expansion, 4) severe proteinuria, and 5) tubulointerstitial fibrosis^9,16,17. Two months old mice were chosen to demonstrate proteomic changes in tubule compartments prior to overt structural lesions. As previously reported and shown in Figure 2, 2-month-old OVE26 mice exhibit glomerular mesangial matrix expansion (Figure 2, green arrow) and severe proteinuria¹⁷, without overt histologic changes to proximal tubules (Figure 2, yellow arrow) in young diabetic mice. Here we present a combined quantitative proteomics approach for the characterization of the whole kidney, medulla, and cortical tubules to elucidate and illustrate the differences in the proteome in each compartment with diabetes.

Protokol

Studies with OVE26 and FVB mice were approved by the University of Louisville Institutional Animal Care and Use Committee (IACUC) guidelines. Transgenic female OVE26 (diabetic; Strain #:005564) and FVB (non-diabetic; background strain; Strain #:001800) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Animals were maintained on a 12 h light/dark cycle at 25 °C, and given free access to water and food. All studies were conducted on 2-month old mice.

1. Animal model

1. Kidney isolation
   1. Anesthetize mice by intraperitoneally administering 80 mg/kg Ketamine and 12 mg/kg Xylazine.
   2. Make a midline abdominal incision with small surgical scissors and gently move the intestines out and to the side of the mouse using swabs to expose the vena cava.
   3. Make a small cut in the vena cava above the right kidney.
   4. Perfuse the mouse through the left ventricle with 20 mL of cold phosphate-buffered saline (PBS: pH 7.4; 210 mg/L KH₂PO₄, 9 g/L NaCl, 726 mg/L Na₂HPO_4·7H₂O) using a peristaltic pump, at a rate of 10 mL/min.
      NOTE: This step is not required if the inclusion of blood proteins and cells in kidneys is not a critical factor in downstream analyses.
   5. Remove kidneys using small surgical scissors. Remove any excess fat from the outside of the kidneys. Weigh the kidneys and place them in cold PBS on ice.
   6. Remove the kidney capsule.
   7. Place kidneys on a glass plate or Petri dish set on ice. Make several transverse cuts through the kidneys using a razor blade (Figure 3) to end up with 3-4 slices between the superior and inferior poles of the kidneys.
   8. Reserve 1-2 middle slices and the two poles (circled kidney slices in Figure 3) from each kidney aside to serve as "whole kidney" samples. Place a portion into 1.5 mL centrifuge tubes and add ice-cold homogenization buffer (10% glycerol, 50 mM HEPES, 100 mM KCl, 2 mM EDTA, 0.1% NP40, 10 mM NaF, 0.25 mM NaVO₃, 1x HALTS protease inhibitor) at approximately 10 µL/mg of tissue sample (based on estimated mass of kidney slices, derived from acquired kidney weight). Leave the tube on ice.
   9. For the remainder of the middle transverse slices, lay the slice flat and carefully slice away the cortex (outer 1 mm) from each slice using a razor blade or scalpel (Figure 3, schematic workflow). Keep the cortex separated from medulla regions for cortical tubule isolation protocol (below, step 1.3).
   10. Place a portion of the dissected medulla into 1.5 mL centrifuge tubes, add ice-cold homogenization buffer as in step 1.1.8, and leave the tube on ice.
   11. Snap freeze in liquid nitrogen all remaining whole kidney and medulla pieces not used for homogenization and store at -80 °C.
2. Alternatively, freeze all separated whole kidney and medulla compartments and store them as described in step 1.1.11. Remove them from storage at a later time for the addition of homogenization buffer as in step 1.1.8.
3. Cortical tubule isolation
   1. Mince the dissected cortex into 1-3 mm pieces on a glass plate or Petri dish with a razor blade, forming a paste.
   2. Digest the minced cortex in 1 mL of type IA collagenase (1 mg/mL) for 30 min, at 37 °C, in a rocking water bath.
   3. Place a 100 µm cell strainer on top of a 50 mL conical tube on ice.
   4. Place the digested cortical suspension onto the 100 µm cell strainer and gently press through the strainer using the plunger of a 10 mL syringe. Wash the top of the strainer with 1 mL of PBS and the underside of the strainer with 1 mL of PBS.
   5. Pass the filtrate in the 50 mL tube through an additional 100 µm strainer, then wash the top of the strainer with 1 mL of PBS.
   6. Pass the filtrate through a 70 µm cell strainer placed over a 50 mL conical tube on ice. Tubules will pass through this strainer into the filtrate (Glomeruli will be retained on the 70 µm strainer). Wash the strainer with 1 mL of PBS.
   7. Spin the final filtrate at 120 × g for 2 min at 4 °C. Discard excess PBS from the tubule pellet.
   8. Check the purity of the cortical tubule pellet by visualization under a microscope, using a 10x objective. If more than 10% of the fraction contains glomeruli, re-suspend the filtrate with 1 mL of PBS and pass through a clean 70 µm cell strainer without any additional washing of the strainer.
   9. Distribute enriched tubule fraction into 1.5 mL centrifuge tubes and spin at 2000 × g for 2 min at 4 °C. Discard the supernatant.
   10. Add homogenization buffer to the tubule pellet as with the whole kidney and medulla (steps 1.1.8 and 1.1.10).
4. Tissue homogenization/Protein extraction
   1. Homogenize each sample type in 1.5 mL microcentrifuge tubes using a plastic pestle specifically for 1.5 mL tubes. If the homogenized suspension is too thick, add additional homogenization buffer as needed.
   2. Leave homogenized suspension on ice for 15 min followed by sonication for 5 min in a bath sonicator (on/off switch only, no adjustable settings on unit), with water in the bath at 25 °C. Leave the samples on ice for 10 min.
   3. Briefly vortex (1000-1500 RPM) homogenate, then triturate 20 times with a pipette and leave on ice for another 15 min.
   4. Triturate the samples several times prior to centrifugation at 13,000 × g for 20 min at 4 °C.
   5. Transfer cleared protein extracts to clean tubes.
   6. Aliquot 30 µL of cleared extract for protein estimation and sample preparation for mass spectrometry analysis. Store the remainder of the samples at -80 °C.

2. Suspension-Trap mini spin column digestion protocol

1. Proteolytic digestion of proteins into tryptic fragments for proteomic analyses
2. Dilute ~40-50 µg of sample (at ~2 µg/ µL) into sample lysis buffer (10% w/v sodium dodecyl sulfate [SDS] in 100 mM triethylammonium bicarbonate (TEA-BC) pH 8.5, 40 mM tris (2-carboxyethyl)phosphine [TCEP]) to a final volume of 46 µL.
3. Reduction and alkylation of proteins
   1. Incubate at 65 °C for 30 min (the final concentration of TCEP is 20 mM).
   2. Add 4 µL of 0.5 M iodoacetamide in liquid chromatography-mass spectrometry (LC-MS) grade water and incubate at room temperature (RT) in the dark for 30 min (the final concentration of iodoacetamide is 40 mM).
4. Add 5 µL of 12% w/w phosphoric acid in LC-MS grade water (dilute 141 µL of 85% phosphoric acid into 859 µL of water for 12% solution).
   1. Alternative to phosphoric acid, use trifluoroacetic acid or formic acid if performing phosphopeptide enrichment¹⁸.
5. Add 350 µL of suspension-trap binding buffer (100 mM TEA-BC in 90% v/v methanol/10% v/v water pH 7.55).
6. Add sample to suspension-trap column. Centrifuge at 4,000 × g for 30 s at RT in a fixed-angle rotor to pass each volume through the column.
7. Wash with 4x 400 µL of suspension-trap binding buffer. Centrifuge at 4,000 x g for 30 s at RT in a fixed-angle rotor to pass each wash through the column.
   NOTE: To aid in the removal of SDS, rotate the column in the rotor 180° after each wash.
8. Centrifuge at 4,000 g for 1 min at RT to completely remove binding buffer (prevents dripping during digestion).
9. Transfer the suspension-trap column to a clean collection tube.
10. Add 2.5-5 µg of trypsin in 125 µL of 50 mM TEA-BC pH 8.5 in LC-MS grade water (Trypsin Protease, MS-Grade). The final ratio of trypsin to the sample is 1:20 up to 1:10.
11. Incubate at 47 °C for 2 h (do not tighten the cap; a thermal mixer set at 0 RPM is preferred). Poking a hole in the cap with a needle may prevent pressure from building in the upper chamber of the suspension trap (increased pressure will cause trypsin solution to drip through the column).
12. Add 80 µL of 50 mM TEA-BC pH 8.5 in LC-MS grade water. Centrifuge at 4,000 g at RT for 1 min in a fixed-angle rotor to pass each digest through the column.
13. Add 80 µL of 0.2% v/v formic acid in LC-MS grade water. Centrifuge at 4,000 g for 1 min at RT in a fixed-angle rotor to collect with digest from step 2.11.
14. Add 80 µL of 50% v/v acetonitrile in LC-MS grade water. Centrifuge at 4,000 g at RT for 1 min in a fixed-angle rotor to collect with digest from step 2.11.
15. Store the suspension trap eluate at -80 °C.
16. Dry the sample in a vacuum concentrator.
17. Store the dried sample at -80 °C.

3. Cleanup with hydrophilic-lipophilic balance (HLB) column

1. Make solutions A (2% v/v acetonitrile/0.1% v/v formic acid) and B (80% v/v acetonitrile/0.1% v/v formic acid).
2. Dissolve the sample in 500 µL of solution A.
3. Place the column in a vacuum manifold and apply gas pressure at ~1-2 mL/min.
4. Add 500 µL of solution B to the HLB column and evacuate at 1-2 mL/min; repeat twice.
5. Add 750 µL of solution A to the HLB column and evacuate at 1-2 mL/min; repeat twice.
6. Place a clean 2 mL microtube in the rack below the HLB column, load the sample in 500 µL of solution A, and gas pressure as above; pass the flow-through into the column a second time.
7. Place the HLB column above the waste tube, add 500 µL of solution A, and evacuate as above; repeat twice.
8. Place the column above a clean 2 mL microtube, add 500 µL of solution B, and evacuate as above; repeat twice.
9. Freeze the eluate at -80 °C, then dry in a vacuum concentrator. Store the dried residue at -80 °C.
10. Dissolve the residue in 20 µL of 2% v/v acetonitrile/0.1% v/v formic acid prior to MS analysis. Use a spectrophotometer to estimate peptide concentration at an absorbance of 205 nm.

4. Mass spectrometry analysis

1. One-dimensional reverse phase liquid chromatography (LC)-MS/MS
   1. Inject an equal mass of peptides (~600 ng) onto 1-dimensional nano-LC and fractionate it on reversed phase C18 columns.
   2. Elute the peptides directly into the MS at a spray voltage of 1.8 kV, with an ion transfer tube maintained at 250 °C.
   3. Acquire the spectra in data-dependent top 20 ion mode where the most intense MS/MS fragment is removed from the analysis queue to improve the depth of ion mapping on lower abundance ions.

5. Data analysis and bioinformatics

1. Data handling procedures
   1. Following spectral assignment and peptide and protein identification in PEAKS 12.0 (LC-MS/MS data analysis software), submit the lists of proteins for analysis in MetaboAnalyst 6.0 (metabolomics data analysis platform) using the single-factor statistical analysis approach (https://www.metaboanalyst.ca/).
   2. Use LC-MS/MS data analysis software to search and filter spectra using strict false discovery rate (FDR) criteria (1% protein and peptide) against the Mouse Reviewed FASTA database.
      NOTE: Alternative search programs that are readily available include Maxquant, Proteome Discoverer, among other widely used options.
   3. Specify carbamidomethylation of cysteine as a fixed modification. Specify oxidation of methionine as a variable modification.
   4. Convert the lists to comma separated values (CSV) format and group/sample labels assigned to each column and row. This format is flexible in the metabolomics data analysis platform.
   5. Impute the missing values using the 1/5 minimum value rule for missing variables.
   6. Filter the data to exclude highly variable values using the interquartile range, where 40% variance is used for the cutoff.
   7. Normalize the values to median intensity, log₁₀ transformed, and mean centered for scaling. Use other normalization approaches, keeping in mind that the results may vary.
   8. Perform T-tests in an unpaired manner with a p-value cutoff < 0.05. Perform multiple testing corrections at this stage.
      NOTE: This study did not perform this correction for the representative dataset for data presentation purposes.
   9. Indicate volcano plots for 1.5 fold change (FC) and p < 0.05.
   10. Generate heatmaps and perform partial least squares discriminant analysis (PLSDA) and statistical (variable of importance of projection [VIP]) analysis of the sample groups.
   11. Potential candidates for follow-up are either robust enough to eclipse 1.5FC and p-val < 0.05 or VIP > 1.0, as indicated in PLSDA analysis.
   12. Generate Venn diagrams to illustrate differences in the proteome of the whole kidney, tubule, and medulla in OVE26 mice.

Sonuçlar

Overall, total protein identifications from each sample type were 1) whole kidney (1438) 2) medulla (2145), and cortical tubules (1859). Following data processing in MetaboAnalyst 6.0, data filtering, and imputation, finally analyzed protein identifications for each kidney compartment were: whole kidney (455), medulla (997), and cortical tubules (896). Figure 4 shows global proteomic changes in the OVE26 diabetic mouse kidney. Label-free quantitative (LFQ) analysis allows for high-depth prot...

Tartışmalar

The methods presented in this technical approach are designed to illustrate comparative proteome analysis of different areas of the kidney. Here, we utilized methods for isolating medulla and cortical tubules in diabetic (OVE26) and control (FVB) mice and performed 1-dimensional LC-MS/MS and bioinformatics analysis to illustrate basic differences in the proteome in each part of the kidney, in addition to the proteome of whole kidneys.

Isolation of the kidney compartments requires careful disse...

Malzemeler

Name	Company	Catalog Number	Comments
Collagenase type 1A	Millipore Signal	C9891
Exploris 480 Orbitrap	Thermofisher	https://www.thermofisher.com/order/catalog/product/BRE725539	MS
Falcon Cell Strainer, 100 µm	VWR	21008-950
Falcon Cell Strainer, 70 µm	VWR	21008-952
Gibco PBS pH 7.4	Thermo	1001023
Halt Protease and Phosphatase Inhibitor Cocktail	VWR	PI78440
Iodoacetamide	Sigma Aldrich	I1149
MetaboAnalyst 6.0	MetaboAnalyst 6.0	https://www.metaboanalyst.ca/	metabolomics data analysis platform
NanoDrop 2000	Thermofisher	https://www.thermofisher.com/order/catalog/product/ND-2000
Oasis HLB column	Waters	186002034
PEAKS 12.0	Bioinformatics Solutions Inc		LC-MS/MS data analysis software
Pestle for 1.5 mL Microtube	Fisher Scientific	NC0782485
Suspension Trap (S-trap)	Protifi	C02-micro-10
TCEP	ThermoFisher Scientific	20490
TEABC	Sigma Aldrich	T7408
Trypsin Protease, MS-Grade	ThermoFisher Scientific	90057
Ultrasonic Cleaner	Cole-Parmer	Model 0884900